Big GoodRx (NASDAQ: GDRX) backer prepares share sale

Rhea-AI Filing Summary

GoodRx Holdings, Inc. (GDRX) received a Rule 144 notice that affiliates of Francisco Partners GP IV, L.P., a 10% stockholder and affiliate, intend to sell Class A Common Stock through Merrill Lynch, Pierce, Fenner & Smith Incorporated on NASDAQ. The filing covers 2,760,995 shares, with an aggregate market value of $10,270,901.40, relative to 107,181,201 Class A shares outstanding. The shares being sold were received upon conversion of Class B Common Stock originally purchased for cash on October 15, 2015 by funds and accounts affiliated with Francisco Partners, including Francisco Partners IV, L.P. and Francisco Partners IV-A, L.P.

Key Figures

Shares to be sold: 2,760,995 shares Aggregate market value of shares to be sold: $10,270,901.40 Shares outstanding: 107,181,201 shares +3 more

6 metrics

Shares to be sold 2,760,995 shares Class A Common Stock covered by the Rule 144 notice

Aggregate market value of shares to be sold $10,270,901.40 Market value associated with 2,760,995 shares of Class A Common Stock

Shares outstanding 107,181,201 shares Class A Common Stock outstanding for GoodRx Holdings, Inc.

Shares originally acquired 84,700,550 shares Class A Common Stock received upon conversion of Class B originally purchased

Original acquisition date 10/15/2015 Date Class B Common Stock was originally purchased for cash

Planned sale date reference 08/19/2026 Date associated with the planned Rule 144 sale

Key Terms

Rule 144, 10% Stockholder, Affiliate, Class A Common Stock

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

10% Stockholder financial

"10% Stockholder, Affiliate"

Affiliate financial

"10% Stockholder, Affiliate"

Class A Common Stock financial

"Class A Common Stock received upon conversion of Class B Common Stock"

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

FAQ

What does the Form 144 filing mean for GoodRx (GDRX)?

The Form 144 indicates affiliates of Francisco Partners GP IV, L.P. plan to sell GoodRx Class A Common Stock under Rule 144. It is a notice of a potential resale by a large stockholder, not an issuance of new shares by GoodRx.

How many GoodRx (GDRX) shares are covered by this Rule 144 notice?

The notice covers 2,760,995 shares of GoodRx Class A Common Stock. These shares have an aggregate market value of $10,270,901.40 and are part of the 107,181,201 shares of Class A Common Stock outstanding.

Who is selling GoodRx (GDRX) shares under this Form 144?

The securities will be sold directly and indirectly by funds and accounts affiliated with Francisco Partners GP IV, L.P., including Francisco Partners IV, L.P. and Francisco Partners IV-A, L.P., which are identified as a 10% stockholder and affiliate.

Through which broker and market will the GoodRx (GDRX) shares be sold?

The planned sales will be executed through Merrill Lynch, Pierce, Fenner & Smith Incorporated on the NASDAQ market. The Rule 144 notice lists this broker and market in connection with the Class A Common Stock resale.

When were the GoodRx (GDRX) shares being sold originally acquired?

The shares to be sold were received upon conversion of Class B Common Stock originally purchased on October 15, 2015 for cash. The filing reports that 84,700,550 shares were acquired on that date by affiliated entities.

What is the reported sale date in the GoodRx (GDRX) Form 144 notice?

The notice lists August 19, 2026 as the relevant date for the planned sale of 2,760,995 shares. This date appears alongside the aggregate market value and shares outstanding for GoodRx’s Class A Common Stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/19/2026 - 02:21 PM Accepted by SEC EDGAR 08/19/2026 - 02:21 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001674067
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	GoodRx Holdings, Inc.
SEC File Number	001-39549
Address of Issuer	2701 OLYMPIC BOULEVARD SANTA MONICA CALIFORNIA 90404
Phone	855-268-2822
Name of Person for Whose Account the Securities are To Be Sold	Francisco Partners GP IV, L.P.
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	10% Stockholder, Affiliate

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A Common Stock	Merrill Lynch, Pierce,Fenner & Smith Incorporated 555 California Street 18th Floor San Francisco CA 94104	2760995	10270901.40	107181201	08/19/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A Common Stock	10/15/2015	Class A Common Stock received upon conversion of Class B Common Stock originally purchased on 10/15/2015	GoodRx Holdings, Inc.			84700550	10/15/2015	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	The reported securities will be sold directly and indirectly by funds and accounts affiliated with Francisco Partner GP IV, L.P., including Francisco Partners IV, L.P. and Francisco Partners IV-A, L.P..
Date of Notice	08/19/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Steve Eisner
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)